Skip to main content
. 2019 Aug;19(3):227–233. doi: 10.17305/bjbms.2019.4204

FIGURE 2.

FIGURE 2

Programmed death ligand-1 (PD-L1) as a biomarker for triple-negative breast cancer (TNBC). (A) Hematoxylin and Eosin (H&E) slide of the high-grade, TNBC not otherwise specified (NOS) with abundant tumor infiltrating lymphocytes (TILs) [×10]; (B) TILs were strongly positive for PD-L1 by immunohistochemistry (clone SP142, Ventana). Note the lack of PD-L1 expression in the cancer cells (×10).